Department of Health and Human Services May 10, 2005 – Federal Register Recent Federal Regulation Documents
Results 1 - 9 of 9
Agency Information Collection Activities; Submission for Office of Management and Budget Review; Allergen Labeling of Food Products Consumer Preference Survey and Experimental Study on Allergen Labeling of Food Products
The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.
Prevention of Salmonella Enteritidis in Shell Eggs During Production; Reopening of Comment Period
The Food and Drug Administration (FDA) is reopening until June 9, 2005, the comment period for the agency's proposed rule entitled ``Prevention of Salmonella Enteritidis in Shell Eggs During Production'' that published in the Federal Register of September 22, 2004 (69 FR 56824). FDA is reopening the comment period to receive comments and other information regarding industry practices and programs that prevent Salmonella Enteritidis (SE)-monitored chicks from becoming infected by SE during the period of pullet rearing until placement into laying hen houses.
Radioactive Drugs for Certain Research Uses; Public Meeting; Reopening of Comment Period
The Food and Drug Administration (FDA) is reopening until July 11, 2005, the comment period on the questions raised and issues addressed in the notice of public meeting, published in the Federal Register of October 5, 2004 (69 FR 59569), on the use of certain radioactive drugs for research purposes without an investigational new drug application (IND) under the conditions set forth in FDA regulations. We are taking this action in response to requests to extend the comment period and to allow additional time to review agency guidance on a related matter.
Draft Guidance for Industry on the Food and Drug Administration's “Drug Watch” for Emerging Drug Safety Information; Availability
The Food and Drug Administration (FDA) is announcing the availability of a draft guidance for industry entitled ``FDA's `Drug Watch' for Emerging Drug Safety Information.'' This document provides guidance about how FDA intends to develop and disseminate important emerging drug safety information concerning marketed drug products to healthcare professionals and patients. This information will appear on an FDA Web page to be called the ``Drug Watch.''
This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply.
